2020-09-27 Application filed by Shanghai National Engineering Research Center for Nanotechnology Co Ltd
Nano coronavirus recombinant vaccine taking graphene oxide as carrier
Abstract
The invention belongs to the field of nano materials and biomedicine, and relates to a vaccine, in particular to development of 2019-nCoV coronavirus nuclear recombinant nano vaccine. The invention also comprises a preparation method of the vaccine and application of the vaccine in animal experiments. The new corona vaccine contains graphene oxide, carnosine, CpG and new corona virus RBD; binding carnosine, CpG and neocoronavirus RBD on the backbone of graphene oxide; the CpG coding sequence is shown as SEQ ID NO 1; the novel coronavirus RBD refers to a novel coronavirus protein receptor binding region which can generate a high-titer specific antibody aiming at the RBD in a mouse body, and provides a strong support for prevention and treatment of the novel coronavirus. Classifications A61K39/12 Viral antigens View 10 more classifications CN112220919A China
Download PDF Find Prior Art Similar Other languagesChineseInventor崔大祥高昂梁辉田静李雪玲沈琦Current Assignee Shanghai National Engineering Research Center for Nanotechnology Co Ltd Worldwide applications 2020 CN Application CN202011031367.1A events 2020-09-27 Application filed by Shanghai National Engineering Research Center for Nanotechnology Co Ltd 2020-09-27 Priority to CN202011031367.1A 2021-01-15 Publication of CN112220919A Status Pending InfoLegal events Similar documents Priority and Related ApplicationsExternal linksEspacenetGlobal DossierDiscuss Description Nano coronavirus recombinant vaccine taking graphene oxide as carrier Technical Field The invention belongs to the field of nano materials and biomedicine, and relates to development of a vaccine development platform. In particular to the development of 2019-nCoV coronavirus nuclear recombinant nano-vaccine. The invention also includes the use of the vaccine in animal testing. Technical Field The vaccine is an ultimate weapon for eliminating major infectious diseases, has the advantages of lowest cost and more advantages of prior enemy than other therapies, undoubtedly becomes hopeful to the public, the smallpox is eliminated by human beings through vaccination, the poliomyelitis cases are reduced by 99 percent, the infectious diseases such as diphtheria are rare, and the incidence rate of diseases such as measles, neonatal tetanus and the like is remarkably reduced. The effect of vaccines on human health is not excessive, and the birth of each new vaccine is a great victory for human beings to overcome an infectious disease! To date, no medical treatment has been able to have such an important, lasting and profound effect on human health as a vaccine; nor is any therapeutic available to eliminate a disease from the earth at the very least cost of a vaccine.
Part of the patent application includes information on its usefulness. So they talk it up. Standard, from my experience (having filed a few utility patents).